Dare Bioscience, Inc. annual report, FY2015

Business context and reporting period

Important entity discrepancy: The request identifies Dare Bioscience, Inc., but the supplied Form 10-K is for Cerulean Pharma Inc. It covers the fiscal year ended December 31, 2015, and was signed March 10, 2016. The filing does not provide Dare Bioscience financial or operating results.

Cerulean was a clinical-stage oncology company developing nanoparticle-drug conjugates. Its lead candidates were CRLX101, in Phase 2 development, and CRLX301, in Phase 1/2a development. It had no approved products and no product-sales revenue.

Financial performance and liquidity

MetricFY 2015FY 2014
Revenue$0$0.08 million
Research and development expense$25.95 million$11.77 million
General and administrative expense$11.22 million$8.59 million
Total operating expenses$37.17 million$20.36 million
Net loss$39.59 million$23.34 million
Basic and diluted loss per share$1.56$1.60
Cash used in operating activities$31.92 million$19.06 million

At year-end, cash and cash equivalents were $75.91 million; working capital was $60.97 million and total assets were $78.23 million. The company reported $21.0 million of Hercules loan principal outstanding (balance-sheet loan payable, net of discounts and financing costs, was $20.32 million). No product gross margin was reported because the company had no product sales. Management believed available cash would fund operating expenses, debt service and planned capital expenditures for at least 12 months from the financial-statement issuance date.

Material changes versus prior comparable period

  • Net loss increased 70% to $39.59 million, principally as operating expenses rose 83%. R&D increased 120%, with CRLX101 spending rising to $19.03 million from $7.24 million, largely due to the RCC trial and other clinical programs.
  • G&A increased 31% to $11.22 million, reflecting company growth and public-company costs.
  • Operating cash use increased by $12.85 million to $31.92 million.
  • Cash rose to $75.91 million from $51.17 million, supported by $37.19 million net proceeds from a 2015 public offering and $21.0 million in Hercules borrowings. Financing cash flow was $57.13 million.
  • Debt increased materially: the company replaced its Lighthouse facility with Hercules financing and drew a further $6.0 million tranche in November. The 2015 net loss also included $2.43 million of interest expense; the $2.49 million debt-extinguishment loss occurred in 2014, not 2015.

Outlook, commentary, risks and unusual items

  • Management expected continued significant expenses and operating losses and stated it would need additional capital to advance its candidates and fund operations. Future financing could dilute shareholders, add debt restrictions, or require partnering or licensing rights.
  • Management expected top-line results from the completed randomized Phase 2 RCC trial in the first half of 2016. The filing describes this as a planned data release, not a financial forecast or assurance of trial success.
  • CRLX301’s every-three-week maximum tolerated dose was 75 mg/m²; dose-limiting toxicities occurred at 90 mg/m² in two of six patients. A weekly schedule was still being evaluated.
  • CRLX101 had previously failed to meet the primary overall-survival endpoint in a Phase 2 NSCLC monotherapy trial. Earlier, single-arm RCC investigator-sponsored results were encouraging but were not confirmatory evidence for the randomized trial.
  • A 2015 CRLX101 drug-substance manufacturing batch failed an out-of-specification test; replacement supply was expected to take several months. The company relied on contract manufacturers and was seeking a commercial-scale drug-product manufacturer.
  • Calando Pharmaceuticals was in Chapter 7 bankruptcy, creating potential uncertainty around licensed intellectual-property rights. The company disclosed possible milestone payments of up to $32.8 million for CRLX101 and approximately $18.0 million per platform product, plus royalties, subject to specified future events.
  • The Hercules loan matures July 1, 2018, bears interest at a stated floor of 7.30%, and is secured by substantially all assets other than intellectual property. It also includes a negative pledge over intellectual property and restrictive covenants. Cerulean lost eligibility for an additional loan tranche of up to $5.0 million after not meeting a trial-start condition by December 15, 2015.
  • Other notable developments included the April 2015 equity offering, the move to a new Waltham facility with a lease through February 2021, and a CEO appointment in March 2015. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not attest to ICFR because of the emerging-growth-company exemption.

Most important facts for investors to verify

  • Confirm the intended issuer: the supplied filing is Cerulean Pharma Inc., not Dare Bioscience, Inc.
  • Review subsequent disclosures and results for the RCC trial, including endpoint results and any changes to development plans.
  • Check cash burn, updated cash runway and financing activity after December 31, 2015; the stated runway depended on assumptions and was not a guarantee.
  • Verify current Hercules debt terms, repayment schedule, collateral and covenant compliance, and any additional financing needs.
  • Track resolution of the CRLX101 manufacturing issue, supplier capacity and the status of commercial-scale manufacturing arrangements.
  • Assess the status and enforceability of Calando-related licenses and the potential milestone, royalty and sublicense-payment obligations.
  • Distinguish clinical signals and preclinical claims from randomized, independently confirmed evidence of safety and efficacy.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.